FindTrial
Sign In

UGN-102

DRUG4 trials

Sponsors

UroGen Pharma Ltd.

Conditions

Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder

Phase 2

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
CompletedNCT03558503
UroGen Pharma Ltd.Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Start: 2018-10-15End: 2020-10-21Updated: 2022-09-16

Phase 3

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
TerminatedNCT04688931
UroGen Pharma Ltd.Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Start: 2021-02-19End: 2023-03-17Updated: 2024-06-06
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
CompletedNCT05136898
UroGen Pharma Ltd.Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Start: 2021-11-30End: 2023-02-02Updated: 2024-09-19
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Active, not recruitingNCT05243550
UroGen Pharma Ltd.Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Start: 2022-03-01End: 2028-03-01Updated: 2026-05-11

Related Papers

Patient experiences with UGN-102 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC): Insights for shared decision making.
Journal of Clinical Oncology2026-05-27
Assessing responses to UGN-102 across EORTC recurrence score groups in patients with recurrent low-grade intermediate-risk NMIBC (ENVISION trial).
Journal of Clinical Oncology2026-05-27
UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial.
2026-03-25
Pharmacokinetics of UGN‑102, an investigational mitomycin‑containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer.
2025-10-11
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study.
2025-06-25
Treatment of low-grade intermediate-risk non-muscle invasive bladder cancer with UGN-102: Results of the phase 3 ATLAS and ENVISION studies.
Journal of Clinical Oncology2025-05-281 citations
Duration of response (DoR) following treatment with UGN-102 in patients with recurrent, low-grade, intermediate-risk, non-muscle invasive, bladder cancer: 18-month DoR data from the phase 3 ENVISION trial.
Journal of Clinical Oncology2025-05-281 citations
Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.
Journal of Clinical Oncology2025-05-28
Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle‐Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial
The Journal of Urology2025-03-064 citations
Treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with UGN-102: Results of the phase 3 ATLAS and ENVISION studies.
Journal of Clinical Oncology2025-02-10
Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.
Journal of Clinical Oncology2025-02-10
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)
The Journal of Urology2024-10-2419 citations
Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer.
2022-05-318 citations
MP54-06 LONGITUDINAL HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN ADULTS WITH NON-MUSCLE-INVASIVE BLADDER CANCER RECEIVING A CHEMOABLATIVE GEL AS A PRIMARY TREATMENT (OPTIMA II: PHASE 2B, SINGLE ARM, OPEN-LABEL TRIAL)
The Journal of Urology2022-04-07
Health-related quality of life outcomes in adults with nonmuscle-invasive bladder cancer receiving a mitomycin-containing reverse thermal gel as a primary treatment (Optima II: Phase 2b, single-arm, open-label trial).
Journal of Clinical Oncology2021-09-211 citations
PD43-02 PRIMARY CHEMOABLATION OF LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER USING UGN-102, A MITOMYCIN-CONTAINING REVERSE THERMAL GEL (OPTIMA II): A PHASE 2b, OPEN-LABEL, SINGLE-ARM TRIAL
The Journal of Urology2021-08-04
UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma.
2020-07-0312 citations
LBA02-03 CAN TURBT BE AVOIDED? PRIMARY CHEMOABLATION WITH A REVERSE THERMAL GEL CONTAINING MITOMYCIN (UGN-102) IN PATIENTS WITH LOW GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER
The Journal of Urology2020-04-012 citations